FDA Brief

Warning letters Devices

FDA warning letter to

Unetixs Vascular, Inc.

High riskIssued Apr 15Posted May 5Center for Devices and Radiological Health

Unetixs Vascular marketed modified ROODRA and 2CP vascular diagnostic devices without required FDA clearance.

What happened

During an inspection of Unetixs Vascular, Inc. in Warwick, RI from September 19, 2025, through December 4, 2025, FDA found that the firm was distributing modified MultiLab Series ROODRA and 2CP vascular diagnostic ultrasound devices without an approved premarket approval (PMA) application or 510(k) clearance (FDA's premarket notification review). The modifications included design and labeling changes from luer connections to bayonet connections to prevent device misconnections, and FDA says they could significantly affect safety and effectiveness and require a new 510(k). FDA noted the changes were implemented to address a complaint of a death caused by air embolism.

What FDA found

  1. FDA says the devices are adulterated (illegally marketed) because the firm has no approved premarket approval (PMA) application or investigational device exemption (IDE, permission to study an unapproved device).

    section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)
  2. FDA says the devices are misbranded (improperly labeled or marketed) because the firm did not notify FDA before commercially distributing the modified device, as required by 510(k).

    section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)
  3. FDA says the design and labeling changes from luer connections to bayonet connections could significantly affect safety and effectiveness, so a new 510(k) submission was required.

    21 CFR 807.81(a)(3)(i)

What FDA wants

FDA tells Unetixs to notify the office in writing within 15 business days of the specific steps taken, how it will prevent recurrence, and documentation of corrections or corrective actions, including a timetable if more time is needed. The response should be emailed to CDRHEnforcement@fda.hhs.gov with subject line 'CMS Case # 724245'.

Who should pay attention

  • hospitals and clinics using ROODRA or 2CP vascular diagnostic systems
  • distributors and buyers of Unetixs vascular devices
  • medical device firms making safety-related design or labeling changes

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  2. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  3. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk
  4. O.N. Diagnostics, LLC

    FDA says O.N. Diagnostics sold changed VirtuOst VFA software without required clearance and had quality and reporting failures.

    High risk